143140-08-3

Usage

Uses

Used in Organic Synthesis:
(S)-(-)-N-METHOXYMETHYL-N-(TRIMETHYLSILYL)METHYL-1-PHENYLETHYLAMINE is used as a building block or intermediate in organic synthesis for the development of new compounds with specific properties. Its unique functional groups and stereochemistry make it a valuable component in the synthesis of pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (S)-(-)-N-METHOXYMETHYL-N-(TRIMETHYLSILYL)METHYL-1-PHENYLETHYLAMINE is used as an active pharmaceutical ingredient (API) or as a key intermediate in the synthesis of drugs. Its specific functional groups and stereochemistry may contribute to the compound's biological activity, making it a potential candidate for the treatment of various diseases or medical conditions.
Used in Materials Science:
(S)-(-)-N-METHOXYMETHYL-N-(TRIMETHYLSILYL)METHYL-1-PHENYLETHYLAMINE may also find applications in materials science, where its unique structure and properties can be utilized to develop new materials with specific characteristics. These materials could have potential uses in various industries, such as electronics, coatings, or adhesives.
It is important to handle and use (S)-(-)-N-METHOXYMETHYL-N-(TRIMETHYLSILYL)METHYL-1-PHENYLETHYLAMINE with care, following proper safety protocols and regulations to ensure its safe and effective use in these applications.

InChI:InChI=1/C14H25NOSi/c1-13(14-9-7-6-8-10-14)15(11-16-2)12-17(3,4)5/h6-10,13H,11-12H2,1-5H3/t13-/m0/s1

Upstream product

• 67-56-1 methanol 
• 50-00-0 formaldehyd 
• 135782-16-0 N-(S)-α-methylbenzyl-N-((trimethylsilyl)methyl)amine 
• 2627-86-3 (S)-1-phenyl-ethylamine 

Downstream Products

• 177696-20-7 (3S,5aS,8aR,8bR)-3-Phenyl-7-((S)-1-phenyl-ethyl)-octahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-b]oxazol-5-one 
• 177696-32-1 (3S,5aR,8aR,8bR)-5a-Bromo-3-phenyl-7-((S)-1-phenyl-ethyl)-octahydro-pyrrolo[3',4':3,4]pyrrolo[2,1-b]oxazol-5-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY

Heterocyclic compounds shown in Formula (I) suitable for inhibiting or regulating the activity of Janus kinase (JAK), particularly tyrosine kinase 2 (TYK2). The compounds are useful for preventing and/or treating relevant JAK-mediated diseases, such as autoimmune diseases, inflammatory diseases, and cancers.

Saturated abnormal NHC-gold(I) complexes: Synthesis and catalytic activity

New saturated abnormal N-heterocyclic carbene complexes of gold(I) have been prepared by a 1,3-dipolar cycloaddition of an in situ generated azomethine ylide with an isocyanogold(I) choride. A series of different substituents on the nitrogen atom of the 1

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I) wherein A is formula (II), formula (III) or formula (IV), and B is formula (V), formula (VI), or formula (VII), can be used in a variety of applications including use as antibacterial agents.

ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES

Compounds of formula (I) wherein: A is Formula (II), Formula (III), or Formula (IV) and B is Formula (V), Formula (VI), or Formula (VII), can be used in a variety of applications including use as antibacterial agents.

Non-stabilized azomethine ylides in [3 + 2] cycloadditions. Pyrrolidinylfuranones from (5S)-5-menthyloxy-4-vinylfuran-2(5H)-one

Upon sonication with lithium fluoride in acetonitrile N-benzyl-N-methoxymethyl(trimethylsilylmethyl)amines 9a-c undergo chemoselective 1,3-dipolar cycloaddition with 4-vinylfuranones 2 and 6 to afford pyrrolidinylfuranones 10, 11a-c and 12a-c. The stereochemistry is assigned by X-ray analyses and proton NMR data comparison of related oxiranylfuranone 13.

Single and double diastereoselection in azomethine ylide cycloaddition reactions with unsaturated chiral bicyclic lactams

Double diastereoselectivity data were analyzed to provide insight into the structural features that influence π-facial selectivity in 1,3-dipolar cycloadditions of chiral and achiral azomethine ylides to chiral, unsaturated bicyclic lactams. Three major steric contributions to the differences in stability (ΔΔG(≠)) between competing cycloaddition transition states were identified. The first major set of steric interactions involve that between the dipoles and the substituents on the left hemisphere (R2) and concave faces of the bicyclic lactams. This effectively hindered both α- and β-approaches in the nonextended transition states. The second major steric interaction was provided by the nonbonded interactions (i) between the R1 angular substituent on the bicyclic lactam and the π-system of the dipole. This interaction was shown to be very significant, causing reversal in π-facial attack of chiral and achiral dipoles when the angular substituent is changed from phenyl or methyl to hydrogen. The high diastereoselectivity observed now opens a route to highly substituted chiral, nonracemic pyrrolidines.